ClinicalTrials.gg
RecruitingNCT05800977ELEVATIONUpdated Dec 31, 2025

A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma

A Phase 1/2 interventional study of Prizloncabtagene autoleucel in Relapsed/Refractory Large B-Cell Lymphoma, sponsored by Shanghai AbelZeta Ltd.. Recruiting at 15 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Shanghai AbelZeta Ltd. (part of AbelZeta Inc.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
112
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, single arm, open-label study. The purpose of the study is to evaluate safety of Prizloncabtagene Autoleucel (Prizlon-cel) and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of Prizlon-cel (Phase 2) in patients with relapsed or refractory large b-cell lymphoma (LBCL).

Read the detailed description

The purpose of the study is to evaluate the safety and efficacy of Prizlon-cel. It includes two phases, Phase 1b and Phase 2. In Phase 1b study, RP2D will be determined. The selected dose will be further evaluated in the Phase 2 study. The study includes the following sequential procedures: Screening, Apheresis and CAR-T manufacturing, Baseline, Lymphodepletion, CAR-T infusion, DLT period (Phase 1b) and Follow-up Visit. Subjects will be followed for at least 2 years after Prizlon-cel infusion, with up to 15 years long-term follow-up on a separate study.

02

Conditions studied

  • Relapsed/Refractory Large B-Cell Lymphoma

Browse trials for

03

In context

Lead sponsor

Shanghai AbelZeta Ltd. is the lead sponsor of 18 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years of age
  • confirmed CD19 or CD20 positive B-cell non-Hodgkin lymphoma, including the following neoplasms as defined by the 2016 WHO classification of lymphoid neoplasms:

    1. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)
    2. Primary mediastinal large B-cell lymphoma (PMBCL)
    3. Transformed follicular lymphoma (tFL)
    4. High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH)
    5. High-grade B-cell lymphoma, NOS (HGBL, NOS)
    6. Follicular lymphoma grade 3B (FL3B)
  • disease after ≥ 2 lines of standard therapy or relapsed after stem cell transplantation (ASCT)
  • At least one per the Lugano 2014 Classification
  • Adequate organ and marrow function

Exclusion criteria

Exclusion Criteria:

  • Prior hematopoietic stem cell transplantation (HSCT) at anytime, or ASCT within 12 weeks prior to apheresis
  • Suspected or confirmed central nervous system involvement
  • Stroke or convulsion history within 6 months of signing form (ICF)
  • disease, immunodeficiency or diseases requiring treatment
  • Uncontrolled active infection
  • Positive surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with detectable hepatitis B virus (HBV) DNA in peripheral blood; positive virus (HCV) antibody with positive HCV RNA in peripheral blood; positive (HIV) antibody; positive syphilis test
  • Severe heart, liver, renal or metabolism disease
  • Inadequate wash-out time for previous anti-tumor treatments prior to apheresis
  • Prior CAR-T therapy
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Prizloncabtagene Autoleucel

    Prizlon-cel will be intravenously administered as a single infusion after lymphodepletion.

    Biological: Prizloncabtagene autoleucel

Interventions

  • Prizlon-cel is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD19 and CD20 antigens

    Also known as: C-CAR039

06

What researchers measure

Primary outcomes

  1. Phase 1b: Incidence and Severity of Treatment-emergent Adverse Events (TEAEs)

    Incidence and severity of TEAEs , including dose limiting toxicities (DLTs)

    Time frame: Up to 90 days after C-CAR039 infusion

  2. Phase 1b: Recommended Phase 2 Dose (R2PD)

    Based on DLTs rates and overall safety profile

    Time frame: Up to 3 months after C-CAR039 infusion

  3. Phase 2: Overall Response Rate (ORR) at 3 months

    Best response rate at 3 months after C-CAR039 infusion, including partial response (PR) and complete response (CR)

    Time frame: Up to 3 months after C-CAR039 infusion

Secondary outcomes

  1. Phase 1b: Incidence and Severity of Adverse Events (AEs)

    Incidence and severity of AEs

    Time frame: Up to 2 years after C-CAR039 infusion

  2. Phase 1b: ORR at 3 months

    Best response rate at 3 months after C-CAR039 infusion, including PR and CR

    Time frame: Up to 3 months after C-CAR039 infusion

  3. Phase 2: Incidence and Severity of Adverse Events (AEs)

    Incidence and severity of any AEs

    Time frame: Up to 2 years after C-CAR039 infusion

  4. ORR

    Best response, including PR and CR

    Time frame: Up to 2 years after C-CAR039 infusion

  5. ORR at 6 months

    Best response rate at 6 months after C-CAR039 infusion, including PR and CR

    Time frame: Up to 6 months after C-CAR039 infusion

  6. Duration of response (DOR)

    The time from the first documented PR or CR to disease progression or death, whichever occurs first

    Time frame: Up to 2 years after C-CAR039 infusion

  7. Time to response (TTR)

    The time from the date of C-CAR039 infusion to the first documented PR or CR

    Time frame: Up to 2 years after C-CAR039 infusion

  8. Progression-free survival (PFS)

    The time from the date of C-CAR039 infusion to the date of first documented disease progression or death

    Time frame: Up to 2 years after C-CAR039 infusion

  9. Overall survival (OS)

    The time from the date of C-CAR039 infusion to the date of death

    Time frame: Up to 2 years after C-CAR039 infusion

  10. Maximal plasma concentration (Cmax)

    Maximal plasma concentration of C-CAR039 in peripheral blood

    Time frame: Up to 2 years after C-CAR039 infusion

  11. Time to reach the maximal plasma concentration (Tmax)

    Time to reach the maximal plasma concentration of C-CAR039 in peripheral blood

    Time frame: Up to 2 years after C-CAR039 infusion

  12. Area under the curve within 28 days (AUC0-28d)

    Area under the curve of C-CAR039 in peripheral blood within 28 days post infusion

    Time frame: Up to 28 days after C-CAR039 infusion

  13. Time of last measurable observed concentration (Tlast)

    Time of last measurable observed concentration of C-CAR039 in peripheral blood

    Time frame: Up to 2 years after C-CAR039 infusion

  14. The B cell percentage changes and CD19/CD20 expression changes in blood

    The B cell percentage changes and CD19/CD20 expression changes in blood by flow cytometry assay before and after C-CAR039 infusion

    Time frame: Up to 2 years after C-CAR039 infusion

  15. Anti-drug (C-CAR039) antibody

    Presence of serum anti-drug (C-CAR039) antibody

    Time frame: Up to 2 years after C-CAR039 infusion

07

Study locations

14 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Mar 2027, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2023
First posted
Apr 6, 2023
StartActual
Feb 22, 2023
Primary completionEst.
Mar 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05800977
Responsible party
Sponsor
First posted
Apr 6, 2023
Start date
Feb 22, 2023
Primary completion
Mar 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Dec 31, 2025

Study contacts

Weili Zhao, M.D., PhD
Contact
zwl_trial@163.com
86-021-64370045
Lugui Qiu, M.D., PhD
Contact
Qiulg@ihcams.ac.cn
86-13821266636
Weili Zhao, M.D., PhD
principal investigator · Ruijin Hospital
Lugui Qiu
principal investigator · Chinese Academy of Medical Sciences Hematology Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prizloncabtagene autoleucel

Start the discussion